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JOURNAL OF HEPATOLOGYTo the Editor:
We read with interest the letter by Liu et al., commenting on our
study about the activation of YAP in early stages of hepatocellular
carcinoma (HCC) development and its potential role as a thera-
peutic target in liver cancer development, recently published in
Journal of Hepatology [1]. In their letter, Liu et al. cite some papers
and reviews proposing an oncosuppressive role of YAP.
Although these studies suggest a role for YAP as a tumor
suppressor in certain contexts, the literature demonstrating an
oncogenic role of YAP in solid experimental and human tumors
is undoubtedly overwhelming. This is particularly true in the case
of HCC. Indeed, many transgenic mice with liver-speciﬁc YAP
overexpression or knockout for Mst1/Mst2 develop primary liver
tumors, morphologically resembling human HCC or cholangio-
carcinomas (CCs) [2–5]. Moreover, increased YAP expression
and its nuclear translocation in neoplastic cells were observed
in chemically-induced HCCs in non-transgenic mice [6]. In rela-
tion to human HCC, many studies have shown a clear association
between YAP expression and tumor development [7–9], with
poor prognosis associated with YAP expression. Notably, a recent
study showed that overall survival rate was lower in HCCs and
combined HCC-CCs (cHC-CCs) that were overexpressing YAP,
compared to those that were not [10]. The latter study also pro-
vided clinicopathological evidence that YAP is overexpressed
more frequently in HCCs displaying stemness-related markers
(EpCAM and CK-19) and in cHC-CCs, compared to HCCs lacking
such expression. Finally, YAP expression is associated to poor
prognosis in several other human malignancies, including non-
small cell lung cancer, gastric cancer and colorectal cancer [11–
13].
Interestingly, some studies provided evidence for the thera-
peutic beneﬁts of YAP inhibition in cancer. Indeed, verteporﬁn
(that inhibits the transcriptional activity of YAP) blocked
YAP-induced liver tumorigenesis in mice and rats [1,14];
VGLL4-mimicking peptide (a natural inhibitor of the YAP-
TEAD interaction) prevented YAP-induced liver tumorigenesis
in mouse models [15] and in human primary gastric cancer
models [16]; cyclic YAP-like peptides (preventing YAP-TEAD
interaction) inhibited tumor growth in a HCC xenograft model
[17].
In conclusion,while YAPmight exert a dual role on tumorigene-
sis, depending on the speciﬁc tissues or cancer types, the results
of our work, together with a vast existing literature, support
the notion that YAP acts as an oncogene in HCC. Moreover,
based on our novel ﬁnding that YAP is overexpressed at very early
stages of the carcinogenic process, YAP can be considered critical
for the development of HCCs and, thus, as a potential therapeutic
target.
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